WO2004012735A3 - New effector conjugates, process for their production and their pharmaceutical use - Google Patents
New effector conjugates, process for their production and their pharmaceutical use Download PDFInfo
- Publication number
- WO2004012735A3 WO2004012735A3 PCT/EP2003/008483 EP0308483W WO2004012735A3 WO 2004012735 A3 WO2004012735 A3 WO 2004012735A3 EP 0308483 W EP0308483 W EP 0308483W WO 2004012735 A3 WO2004012735 A3 WO 2004012735A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- production
- pharmaceutical use
- conjugates
- new effector
- effector conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200500223A EA200500223A1 (en) | 2002-07-31 | 2003-07-31 | NEW CONJUGATES - EFFECTORS, METHOD OF THEIR PRODUCTION AND THEIR PHARMACEUTICAL APPLICATION |
BR0313043-6A BR0313043A (en) | 2002-07-31 | 2003-07-31 | Effector conjugates, process for their production and pharmaceutical use |
CA002492437A CA2492437A1 (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use |
JP2005506073A JP2006505627A (en) | 2002-07-31 | 2003-07-31 | Novel effector conjugates, methods for their production and their pharmaceutical use |
YUP-2005/0082A RS20050082A (en) | 2002-07-31 | 2003-07-31 | New efector conjugates,process for their production and their pharmaceutical use |
IL16603903A IL166039A0 (en) | 2002-07-31 | 2003-07-31 | New effector conjugates process for their production and their pharmaceutical use |
MXPA05001282A MXPA05001282A (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use. |
AU2003253365A AU2003253365A1 (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use |
EP03743752A EP1524979A2 (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use |
NZ537870A NZ537870A (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use |
IS7708A IS7708A (en) | 2002-07-31 | 2005-02-23 | Steering molecule links, their synthesis and pharmacological use |
HR20050186A HRP20050186A2 (en) | 2002-07-31 | 2005-02-25 | New effector conjugates, process for their production and their pharmaceutical use |
NO20051038A NO20051038L (en) | 2002-07-31 | 2005-02-25 | New effector conjugates, processes for their preparation, and their pharmaceutical use |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10234975A DE10234975A1 (en) | 2002-07-31 | 2002-07-31 | New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis |
DE10234975.4 | 2002-07-31 | ||
DE10305098A DE10305098A1 (en) | 2003-02-07 | 2003-02-07 | New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis |
DE10305098.1 | 2003-02-07 | ||
US45167303P | 2003-03-05 | 2003-03-05 | |
US60/451,673 | 2003-03-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004012735A2 WO2004012735A2 (en) | 2004-02-12 |
WO2004012735A3 true WO2004012735A3 (en) | 2004-05-27 |
Family
ID=31498923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/008483 WO2004012735A2 (en) | 2002-07-31 | 2003-07-31 | New effector conjugates, process for their production and their pharmaceutical use |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1524979A2 (en) |
JP (1) | JP2006505627A (en) |
KR (1) | KR20050026033A (en) |
AU (1) | AU2003253365A1 (en) |
BR (1) | BR0313043A (en) |
CA (1) | CA2492437A1 (en) |
CO (1) | CO5700741A2 (en) |
EC (1) | ECSP055626A (en) |
HR (1) | HRP20050186A2 (en) |
IL (1) | IL166039A0 (en) |
IS (1) | IS7708A (en) |
MX (1) | MXPA05001282A (en) |
NO (1) | NO20051038L (en) |
NZ (1) | NZ537870A (en) |
PL (1) | PL374528A1 (en) |
WO (1) | WO2004012735A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9505747B2 (en) | 2012-03-29 | 2016-11-29 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US9550734B2 (en) | 2004-07-23 | 2017-01-24 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9555139B2 (en) | 2007-03-14 | 2017-01-31 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK11452001A3 (en) * | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
GB0221312D0 (en) | 2002-09-13 | 2002-10-23 | Novartis Ag | Organic compounds |
JP2006510626A (en) * | 2002-12-05 | 2006-03-30 | シエーリング アクチエンゲゼルシャフト | Epothilone analogs for site-specific delivery in the treatment of proliferative diseases |
DE10256982A1 (en) | 2002-12-05 | 2004-06-24 | Schering Ag | New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases |
JP2007519681A (en) * | 2004-01-30 | 2007-07-19 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Novel effector complexes, methods for producing them and their pharmaceutical use |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
PE20080102A1 (en) * | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME |
PE20080316A1 (en) | 2006-05-25 | 2008-04-10 | Bristol Myers Squibb Co | AZIRIDINYL-EPOTILONE COMPOUNDS |
WO2008147941A1 (en) | 2007-05-25 | 2008-12-04 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
IT1401451B1 (en) * | 2010-06-10 | 2013-07-26 | Chemi Spa | NEW PROCESS OF PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-IL-METHANOL E (R) -2- [3- (DIISOPROPYLAMINOUS) -1-PHENYLPROPYL] -4- ( hydroxymethyl) Phenol. |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
EA201590622A1 (en) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION |
IL266112B1 (en) * | 2016-10-17 | 2024-03-01 | Pfizer | Anti-edb antibodies and antibody-drug conjugates |
KR102377416B1 (en) * | 2017-06-30 | 2022-03-21 | 엘지디스플레이 주식회사 | Display Device |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0121350A2 (en) * | 1983-03-07 | 1984-10-10 | Smithkline Beckman Corporation | Substituted unsaturated mercaptocarboxylic acids and derivatives as leukotriene antagonists |
WO1994011021A1 (en) * | 1992-11-10 | 1994-05-26 | Cortech, Inc. | Bradykinin antagonists |
US5942555A (en) * | 1996-03-21 | 1999-08-24 | Surmodics, Inc. | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom |
WO2001064650A2 (en) * | 2000-03-01 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research Center | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001083800A2 (en) * | 2000-04-28 | 2001-11-08 | Kosan Biosciences, Inc. | Heterologous production of polyketides |
EP1156053A2 (en) * | 2000-05-18 | 2001-11-21 | National Starch and Chemical Investment Holding Corporation | Adhesion promoters which are silanes comprising carbamate- or urea-groups, and a group with donor or acceptor functionality |
WO2001092255A2 (en) * | 2000-05-26 | 2001-12-06 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
DE10041221A1 (en) * | 2000-08-22 | 2002-03-14 | Deutsches Krebsforsch | Process for the preparation of water-soluble saccharide conjugates and saccharide mimetics by the Diels-Alder reaction and their use as therapeutics or diagnostics |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2003005026A2 (en) * | 2001-07-02 | 2003-01-16 | Amersham Biosciences Uk Limited | Chemical capture reagent |
-
2003
- 2003-07-31 WO PCT/EP2003/008483 patent/WO2004012735A2/en active Application Filing
- 2003-07-31 JP JP2005506073A patent/JP2006505627A/en active Pending
- 2003-07-31 KR KR1020057001569A patent/KR20050026033A/en not_active Application Discontinuation
- 2003-07-31 CA CA002492437A patent/CA2492437A1/en not_active Abandoned
- 2003-07-31 IL IL16603903A patent/IL166039A0/en unknown
- 2003-07-31 BR BR0313043-6A patent/BR0313043A/en not_active IP Right Cessation
- 2003-07-31 MX MXPA05001282A patent/MXPA05001282A/en not_active Application Discontinuation
- 2003-07-31 EP EP03743752A patent/EP1524979A2/en not_active Withdrawn
- 2003-07-31 NZ NZ537870A patent/NZ537870A/en unknown
- 2003-07-31 AU AU2003253365A patent/AU2003253365A1/en not_active Abandoned
- 2003-07-31 PL PL03374528A patent/PL374528A1/en not_active Application Discontinuation
-
2005
- 2005-02-23 IS IS7708A patent/IS7708A/en unknown
- 2005-02-24 EC EC2005005626A patent/ECSP055626A/en unknown
- 2005-02-24 CO CO05017568A patent/CO5700741A2/en not_active Application Discontinuation
- 2005-02-25 HR HR20050186A patent/HRP20050186A2/en not_active Application Discontinuation
- 2005-02-25 NO NO20051038A patent/NO20051038L/en not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0121350A2 (en) * | 1983-03-07 | 1984-10-10 | Smithkline Beckman Corporation | Substituted unsaturated mercaptocarboxylic acids and derivatives as leukotriene antagonists |
WO1994011021A1 (en) * | 1992-11-10 | 1994-05-26 | Cortech, Inc. | Bradykinin antagonists |
US5942555A (en) * | 1996-03-21 | 1999-08-24 | Surmodics, Inc. | Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001064650A2 (en) * | 2000-03-01 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research Center | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2001083800A2 (en) * | 2000-04-28 | 2001-11-08 | Kosan Biosciences, Inc. | Heterologous production of polyketides |
EP1156053A2 (en) * | 2000-05-18 | 2001-11-21 | National Starch and Chemical Investment Holding Corporation | Adhesion promoters which are silanes comprising carbamate- or urea-groups, and a group with donor or acceptor functionality |
WO2001092255A2 (en) * | 2000-05-26 | 2001-12-06 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
DE10041221A1 (en) * | 2000-08-22 | 2002-03-14 | Deutsches Krebsforsch | Process for the preparation of water-soluble saccharide conjugates and saccharide mimetics by the Diels-Alder reaction and their use as therapeutics or diagnostics |
WO2003005026A2 (en) * | 2001-07-02 | 2003-01-16 | Amersham Biosciences Uk Limited | Chemical capture reagent |
Non-Patent Citations (4)
Title |
---|
BERSUKER I B ET AL: "Improved electron-conformational method of pharmacophore identification and bioactivity prediction. Application to angiotensin converting enzyme inhibitors.", JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES. 2000 NOV-DEC, vol. 40, no. 6, November 2000 (2000-11-01), pages 1363 - 1376, XP002274169, ISSN: 0095-2338 * |
KALGUTKAR A S ET AL: "Inactivation of prostaglandin endoperoxide synthase (PGHS) by N-(substituted)maleimides.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1997, vol. 407, 1997, pages 79 - 85, XP009027572, ISSN: 0065-2598 * |
REGHUNADHAN NAIR C P ET AL: "Free radical copolymerisation of N-(4-hydroxy phenyl) maleimide with vinyl monomers: Solvent and penultimate-unit effects", EUROPEAN POLYMER JOURNAL, PERGAMON PRESS LTD. OXFORD, GB, vol. 35, no. 10, 28 July 1999 (1999-07-28), pages 1829 - 1840, XP004179475, ISSN: 0014-3057 * |
WANG LAI-XI ET AL: "Carbohydrate-centered maleimide cluster as a new type of templates for multivalent peptide assembling: Synthesis of multivalent HIV-1 gp41 peptides.", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 11, no. 1, 2 January 2003 (2003-01-02), &, pages 159 - 166, XP002274170, ISSN: 0968-0896 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9550734B2 (en) | 2004-07-23 | 2017-01-24 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9555139B2 (en) | 2007-03-14 | 2017-01-31 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9505747B2 (en) | 2012-03-29 | 2016-11-29 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
IS7708A (en) | 2005-02-23 |
CO5700741A2 (en) | 2006-11-30 |
JP2006505627A (en) | 2006-02-16 |
WO2004012735A2 (en) | 2004-02-12 |
HRP20050186A2 (en) | 2005-10-31 |
IL166039A0 (en) | 2006-01-15 |
MXPA05001282A (en) | 2005-04-28 |
NZ537870A (en) | 2007-03-30 |
ECSP055626A (en) | 2005-04-18 |
AU2003253365A1 (en) | 2004-02-23 |
KR20050026033A (en) | 2005-03-14 |
NO20051038L (en) | 2005-04-06 |
CA2492437A1 (en) | 2004-02-12 |
BR0313043A (en) | 2005-06-14 |
EP1524979A2 (en) | 2005-04-27 |
PL374528A1 (en) | 2005-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004012735A3 (en) | New effector conjugates, process for their production and their pharmaceutical use | |
WO2005074901A3 (en) | New effector conjugates, process for their production and their pharmaceutical use | |
RS20050082A (en) | New efector conjugates,process for their production and their pharmaceutical use | |
WO2003000699A8 (en) | Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain | |
WO2003008431A1 (en) | Process for producing sugar chain asparagine derivative | |
AU2003242083A1 (en) | Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process | |
EP1726299A3 (en) | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture | |
WO2005062977A3 (en) | Prostate cancer specific internalizing human antibodies | |
WO2008003155A3 (en) | Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses | |
CA2474510A1 (en) | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders | |
HK1070350A1 (en) | Protected 3.5-dihydroxy-2.2-dimethyl-valeronitriles for the synthesis of epothilones and derivatives and method for the production and use thereof | |
WO2003026563A3 (en) | Conjugated anti-psychotic drugs and uses thereof | |
WO2002076438A3 (en) | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis | |
WO2004111047A3 (en) | Cycloalkanepyrrolopyridines as dp receptor antagonists | |
AU2003903242A0 (en) | Process for the treatment of wood | |
TW200603215A (en) | Apparatus for manufacturing substrate | |
AU7280300A (en) | Porous organic polymer shaped bodies | |
AU2000273123A1 (en) | Composition for manufacturing formed article comprising starch, pulverized plantfiber or organic fertilizer obtained by treating garbage as main material, meth od for producing the same, method for manufacturing formed article using the same, and formed article and method for use | |
AU2003228202A1 (en) | Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously | |
TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
AU2002358768A1 (en) | Organic dispersions of surface-modified nanoparticles, method for the production and use thereof | |
WO2004037167A3 (en) | Methods of treating dry eye disease with lantibiotics | |
AU2003240042A1 (en) | A process for the biological treatment of ammonium-rich aqueous media | |
WO2005021541A3 (en) | Process for the production of polymorphs of rosiglitazone maleate | |
NO20051794D0 (en) | Process for the preparation of epothilone derivatives, and novel intermediates for the process, and processes for the preparation of such |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0082 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003743752 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 38/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492437 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537870 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005506073 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038181118 Country of ref document: CN Ref document number: 1-2005-500185 Country of ref document: PH Ref document number: 1020057001569 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001282 Country of ref document: MX Ref document number: 2003253365 Country of ref document: AU Ref document number: 374528 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2005-007674 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200500223 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01648 Country of ref document: ZA Ref document number: 05017568 Country of ref document: CO Ref document number: 200501648 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20050186A Country of ref document: HR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001569 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003743752 Country of ref document: EP |